Myriad Pharmaceuticals, Inc. (NASDAQ: MYRX) today announced the presentation of initial clinical data from an ongoing Phase 2a study of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE